SuperworthNeurogene EPS NGNE
Diluted earnings per share by quarter and over the last twelve months, from 2013.
- Last 12 months, to Jun 30, 2026
- −$5.03
- Latest quarter, Q2 FY26
- −$1.53
- Fiscal year 2025
- −$4.24
Neurogene's earnings per share was −$5.03 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.53.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$4.24 | n/a |
| FY2024 | −$4.28 | n/a |
| FY2022 | −$20.72 | n/a |
| FY2021 | −$22.00 | n/a |
| FY2020 | −$13.00 | n/a |
| FY2019 | −$51.60 | n/a |
| FY2018 | −$27.00 | n/a |
| FY2017 | −$42.80 | n/a |
| FY2016 | −$39.20 | n/a |
| FY2015 | −$36.00 | n/a |
| FY2014 | −$62.80 | n/a |
| FY2013 | −$990.20 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.53 | n/a | −$5.03 | |
| Q1 FY26 | −$1.39 | n/a | −$4.55 | |
| Q4 FY25 | −$1.12 | n/a | −$4.24 | |
| Q3 FY25 | −$0.99 | n/a | −$4.12 | |
| Q2 FY25 | −$1.05 | n/a | −$4.32 | |
| Q1 FY25 | −$1.08 | n/a | −$4.36 | |
| Q4 FY24 | −$1.00 | n/a | −$4.28 | |
| Q3 FY24 | −$1.19 | n/a | n/a | |
| Q2 FY24 | −$1.09 | n/a | n/a | |
| Q1 FY24 | −$1.00 | n/a | n/a | |
| Q3 FY23 | −$32.67 | n/a | −$65.26 | |
| Q2 FY23 | −$26.68 | n/a | −$37.31 |
Against its peers
Companies in Drug Manufacturers - General nearest Neurogene's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| NGNENeurogene | −$5.03 | |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| Peer median | $0.97 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Neurogene
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.